After Phase III Amyloidosis Failure Prothena Slashes Workforce In Restructuring

In the backlash following the failure of its late-stage amyloidosis drug, Prothena has announced it will cut 57% of its...

More From BioPortfolio on "After Phase III Amyloidosis Failure Prothena Slashes Workforce In Restructuring"